跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ RIVASTIGMINE PATCH 5 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ RIVASTIGMINE PATCH 5
Authorized
STANDARD
SANDOZ RIVASTIGMINE PATCH 5
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
cfa22f7d08d8f2f4
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
cfa22f7d08d8f2f4
Drug Approval Canada Name
SANDOZ RIVASTIGMINE PATCH 5
Product Name
SANDOZ RIVASTIGMINE PATCH 5
Status
Marketed
Status Date
2016-11-30
Original Market Date
2016-11-30
Din
02426293
Drug Class
Human
Dosage Form
Patch
Route Of Administration
Transdermal
Schedule
Prescription
Ahfs
12:04.00
Atc Original
N06DA03 RIVASTIGMINE
Atc Name
n 06 da 03
Aig Number
0140521007
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
RIVASTIGMINE
4.6 MG / 24 HOUR
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
cfa22f7d08d8f2f4
Type
Standard
Back to Health Canada Approvals